Literature DB >> 9741859

Bayesian decision procedures based on logistic regression models for dose-finding studies.

J Whitehead1, D Williamson.   

Abstract

Early-phase clinical trials, conducted to determine the appropriate dose of an experimental drug to take forward to later trials, are considered. The objective is to find the dose associated with some low probability of an adverse event. A Bayesian model is presented, and a decision-theoretic procedure for finding the optimal doses for each of a series of cohorts of subjects is derived. The procedure is flexible and can easily be conducted using standard statistical software. The results of simulations investigating the properties of the procedure are presented.

Mesh:

Year:  1998        PMID: 9741859     DOI: 10.1080/10543409808835252

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  11 in total

Review 1.  Learning from previous responses in phase I dose-escalation studies.

Authors:  J Whitehead; Y Zhou; N Stallard; S Todd; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

2.  Continual Reassessment and Related Dose-Finding Designs.

Authors:  John O'Quigley; Mark Conaway
Journal:  Stat Sci       Date:  2010       Impact factor: 2.901

3.  Bayesian adaptive designs in single ascending dose trials in healthy volunteers.

Authors:  David Guédé; Bruno Reigner; Francois Vandenhende; Mike Derks; Ulrich Beyer; Paul Jordan; Eric Worth; Cheikh Diack; Nicolas Frey; Richard Peck
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

4.  Continual reassessment and related designs in dose-finding studies.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Stat Med       Date:  2011-02-24       Impact factor: 2.373

5.  Interplay of priors and skeletons in two-stage continual reassessment method.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Stat Med       Date:  2012-08-15       Impact factor: 2.373

6.  A design for phase I trials in completely or partially ordered groups.

Authors:  Mark R Conaway
Journal:  Stat Med       Date:  2017-04-06       Impact factor: 2.373

7.  A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial.

Authors:  Pavel Mozgunov; Suzie Cro; Anne Lingford-Hughes; Louise M Paterson; Thomas Jaki
Journal:  Pharm Stat       Date:  2021-12-10       Impact factor: 1.894

8.  Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.

Authors:  Philip Pallmann; Fang Wan; Adrian P Mander; Graham M Wheeler; Christina Yap; Sally Clive; Lisa V Hampson; Thomas Jaki
Journal:  Clin Trials       Date:  2019-12-19       Impact factor: 2.486

9.  Bridging across patient subgroups in phase I oncology trials that incorporate animal data.

Authors:  Haiyan Zheng; Lisa V Hampson; Thomas Jaki
Journal:  Stat Methods Med Res       Date:  2021-01-27       Impact factor: 3.021

10.  Dose-escalation strategies which use subgroup information.

Authors:  Amy Cotterill; Thomas Jaki
Journal:  Pharm Stat       Date:  2018-06-13       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.